Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Hepatology

• Publication date

  2017-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jhep.2017.04.021PMID 28483676
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CALR exon 9 mutations in idiopathic splanchnic vein thrombosis in an Australian cohort.

  2017cited by this paper
• Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.

  2017cited by this paper
• Incidence rates and case fatality rates of portal vein thrombosis and Budd-Chiari Syndrome

  2017cited by this paper
• Calreticulin mutations and their importance in splanchnic vein thrombosis

  2016cited by this paper
• Molecular analyses in the diagnosis of myeloproliferative neoplasm-related splanchnic vein thrombosis

  2015cited by this paper
• Clinical utility of screening for CALR gene exon 9 mutations in patients with splanchnic venous thrombosis

  2015cited by this paper
• To screen for CALR mutations in patients with splanchnic vein thrombosis?

  2015cited by this paper
• CALR mutations screening should not be studied in splanchnic vein thrombosis

  2015cited by this paper
• Role of calreticulin mutations in the aetiological diagnosis of splanchnic vein thrombosis.

  2015cited by this paper
• Somatic calreticulin mutations in patients with Budd-Chiari syndrome and portal vein thrombosis

  2015cited by this paper
• [CALR gene mutation detection and clinical observation of 150 essential thrombocythemia patients].

  2015cited by this paper
• Detection of the CALR mutation in the diagnosis of splanchnic vein thrombosis

  2015cited by this paper
• Somatic mutations of calreticulin in myeloproliferative neoplasms.

  2013cited by this paper
• Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

  2013cited by this paper
• Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis.

  2012cited by this paper
• Management of hepatic vascular diseases.

  2012cited by this paper
• Acute portal vein thrombosis unrelated to cirrhosis: A prospective multicenter follow‐up study

  2010cited by this paper
• Etiology, management, and outcome of the Budd-Chiari syndrome.

  2009cited by this paper
• The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases.

  2008cited by this paper
• Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis

  2005cited by this paper
• Cause of portal or hepatic venous thrombosis in adults: The role of multiple concurrent factors

  2000cited by this paper
• Risk of hepatic vein thrombosis in relation to recent use of oral contraceptives: A case-control study

  1986cited by this paper
• Risk of hepatic vein thrombosis in relation to recent use of oral contraceptives. A case-control study.

  1986cited by this paper

• Challenges in the management of vascular liver disorders in women in the reproductive period.

  2026cites this paper
• Liver and Vascular Involvement in Philadelphia-Negative Chronic Myeloproliferative Neoplasms—A Narrative Review

  2025cites this paper
• Portal Vein Thrombosis in Patients Without Cirrhosis: Current Practical Approaches and Treatment Strategies

  2025cites this paper
• Etiology and Risk Factors for Splanchnic Vein Thrombosis in Non-Cirrhotic, Non-Neoplastic Patients: A Narrative Review

  2025cites this paper
• Portal hypertension: recommendations for diagnosis and treatment. Consensus document sponsored by the Spanish Association for the Study of the Liver (AEEH) and the Biomedical Research Network Centre for Liver and Digestive Diseases (CIBERehd).

  2024cites this paper
• Portal hypertension: recommendations for diagnosis and treatment. Consensus document sponsored by the Spanish Association for the Study of the Liver (AEEH) and the Biomedical Research Network Center for Liver and Digestive Diseases (CIBERehd).

  2024cites this paper
• Thrombophilia Gene Screen in Cirrhotic Patients with Portal Vein Thrombosis While Awaiting Liver Transplant

  2024cites this paper
• Abdominal surgery in patients with chronic noncirrhotic extrahepatic portal vein obstruction: A multicenter retrospective study

  2024cites this paper
• Exploring the Molecular Aspects of Myeloproliferative Neoplasms Associated with Unusual Site Vein Thrombosis: Review of the Literature and Latest Insights

  2024cites this paper
• Myeloproliferative neoplasms and splanchnic vein thrombosis: Contemporary diagnostic and therapeutic strategies

  2023influential citation
• Management of splanchnic vein thrombosis

  2023influential citation
• Direct oral anticoagulants for the treatment of splanchnic vein thrombosis: A state of art

  2023cites this paper
• The molecular landscape of myeloproliferative neoplasms associated with splanchnic vein thrombosis: Current perspective.

  2023cites this paper
• Splanchnic Vein Thrombosis in Myelofibrosis—An Underappreciated Hallmark of Disease Phenotype

  2023cites this paper
• Molecular Mechanisms Underlying Vascular Liver Diseases: Focus on Thrombosis

  2023cites this paper
• Inferring the initiation and development of myeloproliferative neoplasms

  2022cites this paper
• Thrombose porte aiguë et chronique

  2022cites this paper
• Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: Treatment Considerations and Unmet Needs

  2022cites this paper
• Splanchnic vein thrombosis associated with myeloproliferative neoplasms.

  2022cites this paper
• Multicenter study on recent portal venous system thrombosis associated with cytomegalovirus disease.

  2021cites this paper
• Molecular Genetics of Thrombotic Myeloproliferative Neoplasms: Implications in Precision Oncology

  2021cites this paper
• Extrahepatic Portal Vein Obstruction: Recent Portal Vein Thrombosis and Portal Cavernoma in the Absence of Cirrhosis

  2021cites this paper
• Budd-Chiari Syndrome: Hepatic Venous Outflow Tract Obstruction

  2021cites this paper
• Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL)

  2021cites this paper
• Vascular Disorders

  2021cites this paper
• Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses.

  2020cites this paper
• The utility of thrombophilia testing in patients with newly diagnosed portal vein thrombosis.

  2020cites this paper
• Vascular Disorders of the Liver

  2020cites this paper
• Porto-sinusoidal vascular disease. Vascular liver diseases: Position papers from the francophone network for vascular liver diseases, the French Association for the Study of the Liver (AFEF), and ERN-rare liver.

  2020cites this paper
• Budd-Chiari Syndrome: An Uncommon Cause of Chronic Liver Disease that Cannot Be Missed.

  2020cites this paper
• Risk factors for vascular liver diseases: Vascular liver diseases: position papers from the francophone network for vascular liver diseases, the French Association for the Study of the Liver (AFEF), and ERN-rare liver.

  2020cites this paper
• Next generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis.

  2020cites this paper
• An Update on the Management of Budd–Chiari Syndrome

  2020cites this paper
• Benefits of molecular profiling with next-generation sequencing for the diagnosis and prognosis of myeloproliferative neoplasms in splanchnic vein thrombosis.

  2020cites this paper
• Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases

  2020cites this paper
• Diagnosis, Development, and Treatment of Portal Vein Thrombosis in Patients With and Without Cirrhosis.

  2019cites this paper
• Prevalence of prothrombotic factors in patients with Budd–Chiari syndrome or non‐cirrhotic nonmalignant portal vein thrombosis: A hospital‐based observational study

  2019cites this paper
• Current knowledge in pathophysiology and management of Budd-Chiari syndrome and non-cirrhotic non-tumoral splanchnic vein thrombosis.

  2019cites this paper
• Review article: a multidisciplinary approach to the diagnosis and management of Budd‐Chiari syndrome

  2019cites this paper
• Sensitivity of Kupffer cells and liver sinusoidal endothelial cells to ricin toxin and ricin toxin–Ab complexes

  2019cites this paper
• Budd–Chiari Syndrome: East versus West

  2019cites this paper
• Management of Thrombosis in the Liver Transplant Candidate

  2019cites this paper
• From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms.

  2019cites this paper
• From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms.

  2019cites this paper
• Diagnostic Methods for Cirrhosis and Portal Hypertension

  2018cites this paper
• Pathogenetic mechanisms of thrombosis in patients with myeloproliferative neoplasm

  2018cites this paper
• Budd-Chiari Syndrome and Inferior Vena Cava Obstruction: The Asian Perspective

  2018cites this paper
• Budd-Chiari Syndrome: The Western Perspective

  2018cites this paper
• Detecting CALR Mutations in Splanchnic Vein Thrombosis: Who and How?

  2018cites this paper
• Prevalence of CALR mutations in splanchnic vein thrombosis: A systematic review and meta-analysis.

  2018cites this paper
• Splanchnic Vein Thrombosis in the Myeloproliferative Neoplasms

  2018cites this paper
• Current approaches to challenging scenarios in myeloproliferative neoplasms

  2018cites this paper
• Vascular liver diseases on the clinical side: definitions and diagnosis, new concepts

  2018cites this paper
• Showing one’s true CALRs: spleen size and platelet count help refine the molecular diagnostic pathway for patients with splanchnic vein thrombosis

  2017influential citation
• Calreticulin mutations and their importance in Budd-Chiari syndrome.

  2017cites this paper
• Reply to: "Calreticulin mutations and their importance in Budd-Chiari syndrome".

  2017cites this paper
• Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease

  2017cites this paper
• World Journal of Hepatology

  year unknowncites this paper